Please assess the completion status of the following clinical trial:

Trial Title: Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Capable of giving informed consent~* Informed consent as documented by signature~* Male and female in- and outpatients 18 years to 60 years of age~* Right-handedness~* DSM-IV-diagnosis of mild or moderate major depressive episode without psychotic features (based on clinical assessment and confirmed by the SCID Interview)~* Score of ≥ 10 and ≤40 on the Montgomery-Asberg Depression Rating Scale (MADRS) at both screening and baseline visits.~* Drug free from any psychotropic medication for at least two weeks (or five weeks for fluoxetine) before enrolling in the study~* Judged clinically not to be a serious suicide risk~* Good physical health with no unstable medical conditions, as determined by medical history, physical examination, routine blood labs, electrocardiogram, urineanalysis, and urine toxicology~* Normal level of language comprehension and German or Swiss-German as first language~* Willing to refrain from drinking alcohol the day before testing days, from drinking alcohol and caffeinated drinks during the testing days and from consuming psychoactive substances 2 weeks before enrolling in the study and for the remainder of the study~* Women of childbearing potential must be using an effective, established method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices. Note: female participants who are surgically sterilised / hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential.~* Have a family member or friend who can pick them up and stay with them overnight after the psilocybin administration sessions (driving is forbidden at drug treatment days)~Exclusion Criteria:~* Lifetime history of bipolar disorder (I, II, not otherwise specified)~* Lifetime history of schizophrenia, schizoaffective disorder, or psychosis not otherwise specified~* History of DSM-IV drug or alcohol dependence or abuse (except for caffeine or nicotine) within three months prior to enrollment~* Comorbid Axis I anxiety disorder diagnoses will be permitted if they do not require current treatment~* Family history of schizophrenia or schizoaffective disorder, or bipolar disorder type 1 (first or second degree relatives)~* Lifetime history of hallucinogen use on more than 10 occasions~* Getting psychotherapeutic or psychological treatment from third parties during the study is forbidden~* Abnormal electrocardiogram~* Any unstable illness as determined by history or laboratory tests~* BMI \<17 or \>35~* Uncorrected hypo- or hyperthyroidism~* Women who are pregnant or breast feeding, or have the intention to become pregnant during the course of the study~* Contraindications to magnetic resonance imaging (MRI safety form)~* During the study, new use or dose changes of already existing concomitant medication without prior informing the investigators is forbidden~* Allergy, hypersensitivity, or other adverse reaction to previous use of psilocybin or other hallucinogens~* High risk of adverse emotional or behavioral reaction based on investigator's clinical evaluation (e.g., evidence of serious personality disorder, antisocial behavior, serious current stressors, lack of meaningful social support)~* Participation in another study with investigational drug within the 30 days preceding and during the present study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): one oral dose of 100% mannitol (placebo)
- Psilocybin (Type: ACTIVE_COMPARATOR): one oral dose of 0.215mg/kg psilocybin (verum)

Based on this trial design, predict the completion outcome and termination type (if applicable).